Pharmicell (KO:005690) — Stock Price
Pharmicell (KO:005690) is currently trading at ₩11700.00 KRW, up 4.56% today. Over the past 52 weeks, shares have ranged between ₩8760.00 and ₩20250.00. This page tracks Pharmicell's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Pharmicell.
Pharmicell (005690) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Pharmicell's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Pharmicell Income Statement — Revenue, Profit & Earnings by Year
Pharmicell's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩64.85 Billion | ₩56.23 Billion | ₩60.18 Billion | ₩51.81 Billion | ₩37.75 Billion |
| Cost of Revenue | ₩43.52 Billion | ₩40.74 Billion | ₩36.36 Billion | ₩28.10 Billion | ₩19.97 Billion |
| Gross Profit | ₩21.33 Billion | ₩15.49 Billion | ₩23.82 Billion | ₩23.71 Billion | ₩17.78 Billion |
| Research & Development | ₩7.89 Billion | ₩6.54 Billion | ₩6.88 Billion | ₩6.99 Billion | ₩4.31 Billion |
| SG&A | ₩3.20 Billion | ₩2.97 Billion | ₩2.41 Billion | ₩2.55 Billion | ₩1.51 Billion |
| Total Operating Expenses | ₩60.20 Billion | ₩54.93 Billion | ₩51.31 Billion | ₩43.95 Billion | ₩30.52 Billion |
| Operating Income | ₩4.66 Billion | ₩1.30 Billion | ₩8.87 Billion | ₩7.86 Billion | ₩7.23 Billion |
| EBITDA | — | — | ₩8.90 Billion | ₩12.93 Billion | ₩7.10 Billion |
| EBIT | — | — | — | — | ₩7.10 Billion |
| Interest Expense | ₩101.37 Million | ₩866.88 Million | ₩746.20 Million | ₩1.68 Billion | ₩84.89 Million |
| Income Before Tax | ₩6.26 Billion | ₩4.73 Billion | ₩5.97 Billion | ₩9.45 Billion | ₩5.24 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ₩6.33 Billion | ₩3.58 Billion | ₩8.26 Billion | ₩9.45 Billion | ₩5.24 Billion |
Pharmicell Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Pharmicell's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩99.26 Billion | ₩92.52 Billion | ₩109.65 Billion | ₩94.33 Billion | ₩69.74 Billion |
| Total Current Assets | ₩48.04 Billion | ₩43.17 Billion | ₩62.36 Billion | ₩65.04 Billion | ₩42.94 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩2.94 Billion | ₩301.28 Million | ₩11.60 Billion | ₩10.03 Billion | ₩5.01 Billion |
| Net Receivables | ₩16.16 Billion | ₩6.87 Billion | ₩10.75 Billion | ₩6.57 Billion | ₩10.16 Billion |
| Inventory | ₩19.78 Billion | ₩20.87 Billion | ₩22.86 Billion | ₩18.44 Billion | ₩6.34 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | ₩5.54 Billion | ₩5.54 Billion | ₩5.54 Billion | ₩5.54 Billion | ₩5.54 Billion |
| Total Liabilities | ₩12.83 Billion | ₩12.12 Billion | ₩32.98 Billion | ₩30.46 Billion | ₩12.64 Billion |
| Total Current Liabilities | ₩7.65 Billion | ₩7.76 Billion | ₩28.55 Billion | ₩24.94 Billion | ₩6.51 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | ₩2.32 Billion | — | — |
| Total Stockholder Equity | ₩86.44 Billion | ₩80.40 Billion | ₩76.66 Billion | ₩63.87 Billion | ₩57.11 Billion |
| Retained Earnings | ₩7.13 Billion | ₩1.09 Billion | ₩-146.85 Billion | ₩-154.41 Billion | ₩-161.17 Billion |
Pharmicell Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Pharmicell generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩3.50 Billion | ₩11.81 Billion | ₩7.91 Billion | ₩-5.22 Billion | ₩8.98 Billion |
| Capital Expenditures | ₩4.34 Billion | ₩6.02 Billion | ₩18.96 Billion | ₩4.32 Billion | ₩742.73 Million |
| Free Cash Flow | ₩-839.98 Million | ₩5.79 Billion | ₩-11.04 Billion | ₩-9.54 Billion | ₩8.24 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩3.06 Billion | ₩2.84 Billion | ₩2.19 Billion | ₩1.74 Billion | ₩1.77 Billion |
| Change in Cash | ₩-5.46 Billion | ₩-634.69 Million | ₩-11.85 Billion | ₩5.27 Billion | ₩4.23 Billion |
Pharmicell Earnings History — EPS Actual vs. Analyst Estimates
Track Pharmicell's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 06, 2026 | — | — | — |
| Feb 09, 2026 | — | — | — |
| Nov 04, 2025 | 146.26 | — | — |
| Aug 11, 2025 | 123.07 | — | — |
| May 08, 2025 | 140.93 | — | — |
| Feb 10, 2025 | 69.23 | — | — |
| Nov 05, 2024 | 11.90 | — | — |
| Aug 13, 2024 | 47.13 | — | — |